PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE

• A. Lal,
• R. C. Brown,
• T. Coates,
• T. Kalfa,
• J. Kwiatkowski,
• J. Brevard,
• C. Trenor,
• K. Wood,
• S. Sheth

Affiliations

A. Lal

1 University of California San Francisco, San Francisco

R. C. Brown

2 Children’s Healthcare of Atlanta, Atlanta

T. Coates

3 University of Southern California Keck School of Medicine, Los Angeles

T. Kalfa

4 Cincinnati Children’s Hospital Medical Center, Cincinnati

J. Kwiatkowski

5 Children’s Hospital of Philadelphia and Perelman School of Medicine, Philadelphia

J. Brevard

6 Forma Therapeutics, Inc., Watertown

C. Trenor

6 Forma Therapeutics, Inc., Watertown

K. Wood

6 Forma Therapeutics, Inc., Watertown

S. Sheth

7 Weill Cornell Medicine, New York, United States of America